Belt-Tightening Biogen Looks To Narrow Therapeutic Focus
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Scangos Leaves Biogen Transformed And Transitioning
CEO George Scangos built Biogen into an innovative biotech, but his departure, coming as the company dusts itself off after a fall from glory, increased speculation Biogen could become a takeout target.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.